Abstract: This invention relates to compounds, compositions and methods for treating leukemia, such as acute myeloid leukemia, in subjects where one or more mutations in FLT3 kinase are present.

Abstract: The present invention provides a therapeutic composition for intractable leukemia comprising a drug (a) and a drug (b), wherein the drug (a) is a compound represented by the following formula (I), a salt thereof, or a prodrug thereof: wherein, Ar1 is a substituted or unsubstituted arylene group; Ar2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aralkyl group; L is an oxygen atom, —NHCO—, or —CONH—; X1 is CH; X2 and X3 are CH and a nitrogen atom, respectively; Y is an ethylene group; m is 0; and Z1 and Z2 form a substituted or unsubstituted monocyclic heterocyclic group comprising X3 and having two nitrogen atoms as ring members, and the drug (b) is a steroidal anti-inflammatory drug; and relates to a therapy for intractable leukemia.

Abstract: The present invention provides a therapeutic composition for intractable leukemia comprising a drug (a) and a drug (b), wherein the drug (a) is a compound represented by the following formula (I), a salt thereof, or a prodrug thereof: wherein, Ar1 is a substituted or unsubstituted arylene group; Ar2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aralkyl group; L is an oxygen atom, —NHCO—, or —CONH—; X1 is CH; X2 and X3 are CH and a nitrogen atom, respectively; Y is an ethylene group; m is 0; and Z1 and Z2 form a substituted or unsubstituted monocyclic heterocyclic group comprising X3 and having two nitrogen atoms as ring members, and the drug (b) is a steroidal anti-inflammatory drug; and relates to a therapy for intractable leukemia.

Abstract: This invention relates to an agent for treating or inhibiting recurrence of acute myeloid leukemia and an agent for inhibiting growth of leukemia stem cells comprising a compound represented by formula (I) or a salt thereof: wherein Ar1 and Ar2 each represent aryl or heteroaryl; L represents O, S, NH, NHCO, or CONH; X represents CH or N; Y represents C1-3-alkylene; Z1 represents hydrogen, C1-6-alkyl, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, di(C1-6-alkyl)amino-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, or carboxy-C1-6-alkyl; and Z2 represents C1-6-alkyl, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, di(C1-6-alkyl)amino-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, or carboxy-C1-6-alkyl, Z1 and Z2 may, together with adjacent nitrogen, form a heterocyclic group containing as a ring member one or more hetero atoms, in addition to the nitrogen adjacent to Z1 and Z2.

Abstract: The invention relates to a method of selectively expanding human leukemic cells in a non-adult NOD/SCID/IL2rgnull mouse by transplanting a substance containing a leukemic stem cell derived from a human acute myelogenous leukemia patient to the mouse. In addition, the invention relates to screening for a medicament capable of eradicating leukemic stem cell (LSC), consideration of treatment methods suitable for individual patients, identification of a differentially expressed gene and the like, using a mouse with expanded human leukemic cells.

Abstract: This invention relates to an agent for treating or inhibiting recurrence of acute myeloid leukemia and an agent for inhibiting growth of leukemia stem cells comprising a compound represented by formula (I) or a salt thereof: wherein Ar1 and Ar2 each represent aryl or heteroaryl; L represents O, S, NH, NHCO, or CONH; X represents CH or N; Y represents C1-3-alkylene; Z1 represents hydrogen, C1-6-alkyl, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, di(C1-6-alkyl)amino-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, or carboxy-C1-6-alkyl; and Z2 represents C1-6-alkyl, amino-C1-6-alkyl, C1-6-alkylamino-C1-6-alkyl, di(C1-6-alkyl)amino-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkoxy-C1-6-alkyl, or carboxy-C1-6-alkyl, Z1 and Z2 may, together with adjacent nitrogen, form a heterocyclic group containing as a ring member one or more hetero atoms, in addition to the nitrogen adjacent to Z1 and Z2.

Abstract: The invention provides a test method for predicting the initial onset or a recurrence of acute myeloid leukemia (AML) comprising (1) measuring the expression level of human leukemic stem cell (LSC) marker genes in a biological sample collected from a subject for a transcription product or translation product of the gene as an analyte and (2) comparing the expression level with a reference value; an LSC-targeting therapeutic agent for AML capable of suppressing the expression of a gene selected from among LSC marker genes or a substance capable of suppressing the activity of a translation product of the gene; a method for producing a sample containing hematopoietic cells for autologous transplantation or allogeneic transplantation for AML patients, comprising obtaining an LSC-purged sample with at least 1 kind of LSC marker as an index; and a method of preventing or treating AML.

Abstract: The present invention provides a drug capable of initiating the progression of the cell cycle of leukemia stem cells to overcome the resistance of the leukemia stem cells to cell cycle-dependent chemotherapeutic agents, and a drug for suppressing recurrence of leukemia containing the same, and the like, an agent containing G-CSF, wherein the agent is for inducing the progression of the cell cycle of leukemia stem cells, a drug for suppressing recurrence of leukemia containing a combination of G-CSF and a cell cycle-dependent antitumor agent, and the like.

Abstract: The invention provides a test method for predicting the initial onset or a recurrence of acute myeloid leukemia (AML) comprising (1) measuring the expression level of human leukemic stem cell (LSC) marker genes in a biological sample collected from a subject for a transcription product or translation product of the gene as an analyte and (2) comparing the expression level with a reference value; an LSC-targeting therapeutic agent for AML capable of suppressing the expression of a gene selected from among LSC marker genes or a substance capable of suppressing the activity of a translation product of the gene; a method for producing a sample containing hematopoietic cells for autologous transplantation or allogeneic transplantation for AML patients comprising obtaining an LSC-purged sample with at least 1 kind of LSC marker as an index; and a method of preventing or treating AML.

Abstract: The invention relates to a method of selectively expanding human leukemic cells in a non-adult NOD/SCID/IL2rgnull mouse by transplanting a substance containing a leukemic stem cell derived from a human acute myelogenous leukemia patient to the mouse. In addition, the invention relates to screening for a medicament capable of eradicating leukemic stem cell (LSC), consideration of treatment methods suitable for individual patients, identification of a differentially expressed gene and the like, using a mouse with expanded human leukemic cells.

Abstract: Provided are a B cell-derived iPS cell generated using a convenient technique, a technology for providing a human antibody at low cost using the iPS cell, an immunologically humanized mouse prepared using cells differentiated from the iPS cell, and the like. Also provided are a cloned cell obtained by contacting a B cell with nuclear reprogramming factors excluding C/EBP? and Pax5 expression inhibiting substances, particularly nucleic acids that encode Oct3/4, Sox2, Klf4 and c-Myc, wherein the cloned cell has an immunoglobulin gene rearranged therein and possesses pluripotency and replication competence (B-iPS cell).

Abstract: It is an object of the present invention to provide an immunodeficient animal capable of generating human-derived lymphoid cells, a human-derived lymphoid cell, and a method for producing a human antigen-specific antibody. The means for solving the aforementioned object is: an immature immunodeficient mammal into which human-derived hematopoietic precursor cells have been transplanted, and which is able to generate said human-derived hematopoietic cells or immunocompetent cells; and a method for producing a human-derived antibody, which is characterized in that it comprises recovering immunocompetent cells from the above-described mammal, culturing the immunocompetent cells, and collecting a human-derived antibody from the obtained culture product.

Abstract: It is an object of the present invention to provide an immunodeficient animal capable of generating human-derived lymphoid cells, a human-derived lymphoid cell, and a method for producing a human antigen-specific antibody. The means for solving the aforementioned object is: an immature immunodeficient mammal into which human-derived hematopoietic precursor cells have been transplanted, and which is able to generate said human-derived hematopoietic cells or immunocompetent cells; and a method for producing a human-derived antibody, which is characterized in that it comprises recovering immunocompetent cells from the above-described mammal, culturing the immunocompetent cells, and collecting a human-derived antibody from the obtained culture product.

Abstract: It is intended to provide a method of regenerating an organ or a part thereof which comprises transplanting bone marrow or hematopoietic stem cells into an injured mammal or a mammal having an injured in organ or a part thereof; a method of treating injury: a method of producing an organ or a part thereof; and an organ or a part thereof produced by this method.

Abstract: A method of designing a superconductivity employing apparatus includes the steps of causing a magnetism generating disk-shaped floatable portion (4) to face a disk-shaped fixed portion (2) capable of exhibiting superconductivity with a gap (G) therebetween; initializing the fixed portion (2) to reach a superconducting state at a position where the floatable portion (4) is spaced away from the fixed portion (2) to such an extent that its magnetic field does not influence the fixed portion (2); and using properly first, second, and n-th approach characteristics (S1, S2, Sn) when a difference between an n-th approach characteristic (Sn) and the second characteristic (S2) is smaller than a difference between the first and second characteristics (S1, S2), where the first approach characteristic (S1) is a characteristic of a magnetic floating force obtained by allowing the floatable portion (4) to approach the fixed portion (2), the second approach characteristic (S2) is a characteristic of a magnetic floating forc

Abstract: In a reverse-charge prevention apparatus (24) including a 1st breaker (25) for connecting or disconnecting an electric power system (A) to or from a distributed electric power apparatus (11), in which the 1st breaker (25) is switched off when the distributed electric power apparatus (11) is disconnected from the electric power system (A) by switching off a 2nd breaker (F) disposed in the electric power system (A) so that reverse-charge from the distributed electric power apparatus (11) to the electric power system (A) is prevented, the reverse-charge prevention apparatus (24) further includes a disturbance generator (20) for slightly varying electric power outputted by the distributed electric power apparatus (11) regularly with a given period; a variable period extraction circuit and a filter (26, 27) for extracting a variable period same in period to the given period, the variable period existing in a period of an alternating-current voltage outputted by the distributed electric power apparatus (11); and a

Abstract: An image forming apparatus of the type collecting a toner remaining on the surface of an image carrier after image transfer and returning it to a developing unit to use it again. The apparatus separates the toner from paper dust and other impurities before returning the toner to the developing unit on the basis of differences in charge, weight and volume between the toner and the impurities. The toner is returned via an eletrostatic conveyor.

Abstract: A superconducting bearing comprises a rotating member A and a fixed member B, one of which is provided with a superconducting member (5) while the other is provided with a magnet (8). The superconducting member (5) includes a superconductor (4) for floating the magnet (8) and a support (3) for supporting the superconductor (4). The magnet (8) includes a ring-like magnet (11) which is coaxial with the axis of the rotary member A, and the ring-like magnet (11) and the superconductor member (5) are so disposed as to face each other with a gap between them. A magnetic flux diffusion member (13) is disposed on the surface of the ring-like magnet (11) opposed to the superconductor (5). The ring-like magnet (11) comprises two ring-like magnets (11A and 11B) having mutually different diameters, and the ring-like magnets (11A and 11B) are magnetized so that the directions of magnetic fluxes face slantingly with one another.

Abstract: An electric vehicle in which each of the driving wheels is adapted to be driven and regeneratively braked by its individual and independently controlled driving motor, and the driving motors are independently controlled in response to sensors detecting the travel of the vehicle including wheel rotation sensors, steering angle sensors, and acceleration and braking sensors.

Abstract: A superconduction bearing is provided in which the load capacity and rigidity of a rotary member are improved, run-out of the rotary member is prevented to support the rotary member in a stable, non-contacting manner, and manufacturing cost is reduced. The superconduction bearing includes a rotary member and a disk formed on the rotary member. The disk has permanent magnets provided thereon. The permanent magnets are magnetized to have opposite poles on top and bottom sides thereof. A permanent magnet section is thus formed by the disk and the permanent magnets. Superconductors are concentrically provided for rotatably supporting the rotary member. The permanent magnet section and the superconductor section are positioned opposite to each other. The width and thickness of the permanent magnets are set to 5 to 10 times the distance between the permanent magnet section and the superconductor section.